Reference

Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder

All Rights Reserved. Darifenacin: a selective M3 muscarinic receptor antagonist for the treatment of overactive bladder. Smith, Phillip P.; Lai, H. Henry; Appell, Rodney A. (Division of Voiding Dysfunction & Female Urology, Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA). Therapy, 3(6), 723-732 (English) 2006 Future Drugs Ltd. CODEN: THERCR. ISSN: 1475-0708. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Overactive bladder is a common and distressing disorder that imposes significant financial and quality-of-life costs. The current therapeutic paradigm aims to decrease detrusor overactivity via blockade of bladder M3 muscarinic receptors, the primary cholinergic receptors responsible for detrusor contraction. However, systemic antimuscarinic adverse effects, such as dry mouth and constipation, limit the tolerability of antimuscarinic treatment. Therefore, a uroselective M3 receptor antagonist would be considered optimal therapy for overactive bladder. Darifenacin (Enablex) is the most recent antimuscarinic drug approved for the treatment of overactive bladder. It demonstrates M3 receptor selectivity, but is not M3 specific. 133099-07-7 which is the cas registry number of one of substances is just one of reagents here. Despite animal data suggesting uroselectivity, it is not sufficiently uroselective in therapeutic use. While effective in reducing symptoms related to overactive bladder, dry mouth and constipation remain common. There are no comparative trials comparing darifenacin with existing agents, therefore it is not known if darifenacin represents an improvement over existing agents. .